Ionis Pharmaceuticals traded at $74.79 this Thursday April 2nd, decreasing $0.34 or 0.45 percent since the previous trading session. Looking back, over the last four weeks, Ionis Pharmaceuticals lost 4.92 percent. Over the last 12 months, its price rose by 162.24 percent. Looking ahead, we forecast Ionis Pharmaceuticals to be priced at 72.54 by the end of this quarter and at 66.18 in one year, according to Trading Economics global macro models projections and analysts expectations.
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on two core franchises: neurology and cardiometabolic. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. Its products in pipeline include tofersen for SOD1-ALS, eplontersen (IONIS-TTR-LRX) for TTR, IONIS-APOCIII-LRx for familial chylomicronemia syndrome (FCS), pelacarsen for lipoprotein(a) (Lp), driven cardiovascular disease and ION363 for amyotrophic lateral sclerosis (ALS), with mutations in the fused in sarcoma gene (FUS).